InMed (INM) news
Recent news
Inmed: Mentari deal expected to close in 2H 2026
InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced that the acquisition of Mentari is expected to close in the second half of 2026, according to recent disclosures. The deal, which is still in the final stages of negotiation and regulatory review, is anticipated to expand InMed’s pipeline of…
AInvest Wire · May 19, 2026Inmed: $290M placement of Mentari to fund company operations through 2028
InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced a $290 million private placement of its subsidiary, Mentari, to fund company operations through 2028. The capital raise is intended to support the continued development of InMed’s pipeline of proprietary small molecule drug candidates,…
AInvest Wire · May 19, 2026Inmed: combined co. to have equity value of about $421.4M
InMed Pharmaceuticals Inc. is projected to have an equity value of approximately $421.4 million as of May 2026, reflecting the company’s transformation into a revenue-generating entity following its 2021 acquisition of BayMedica Inc. . The acquisition, which was structured as a share-based…
AInvest Wire · May 19, 2026Inmed Pharmaceuticals & Mentari Therapeutics report merger
AInvest Wire · May 19, 2026ImportantFINMA: Systematic deficiencies could not be corrected
AInvest Wire · Feb 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.